Oncolytics Biotech Inc (ONC)

Currency in CAD
1.42
+0.03(+2.16%)
Closed·
Showing Oncolytics Biotech historical data. For real-time data please try another search
Fair Value
Day's Range
1.391.44
52 wk Range
0.452.08
Key Statistics
Bid/Ask
1.39 / 1.42
Prev. Close
1.39
Open
1.42
Day's Range
1.39-1.44
52 wk Range
0.45-2.08
Volume
109.63K
Average Volume (3m)
282.49K
1-Year Change
-4.7%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ONC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Oncolytics Biotech Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Oncolytics Biotech Inc Company Profile

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

Oncolytics Biotech Inc SWOT Analysis


Pelareorep Promise
Oncolytics Biotech's lead candidate, pelareorep, shows potential in cancer treatment, with crucial BRACELET-1 trial results expected in late 2024
Regulatory Tailwinds
FDA support for progression-free survival as a primary endpoint could accelerate pelareorep's path to market, streamlining the approval process
Financial Outlook
Analysts set a $6.00 price target for Oncolytics Biotech, representing significant upside potential from its current trading price of $1.40
Strategic Challenges
Delayed partnership expectations and the speculative nature of oncolytic virus research pose risks, balanced against the potential for groundbreaking cancer therapies
Read full SWOT analysis

Compare ONC to Peers and Sector

Metrics to compare
ONC
Peers
Sector
Relationship
P/E Ratio
−6.5x−8.5x−0.7x
PEG Ratio
−2.12−0.110.00
Price/Book
32.4x0.6x2.6x
Price / LTM Sales
-83.3x3.4x
Upside (Analyst Target)
260.9%0.0%36.2%
Fair Value Upside
Unlock−4.5%4.1%Unlock

Earnings

Latest Release
Aug 08, 2025
EPS / Forecast
-0.07 / -0.0885
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ONC Income Statement

People Also Watch

3.135
PGEN
-3.54%
1.540
CGTX
-0.65%
3.770
NEON
-0.26%
1.090
OTLK
+2.83%
1.5300
HOTH
-3.16%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.